OpenDNA has introduced two next-generation genetic risk tests designed to give physicians and patients a broader, more actionable picture of health risk: PolyRisk+, a polygenic risk score (PRS) panel, and an expanded TotalRisk+ test that integrates both polygenic and monogenic data with clinical information.
Together, these new offerings extend coverage to 30 conditions across eight disease categories, including cardiometabolic, cancer, autoimmune, eye, respiratory, neurological, mental health, and women’s health.
“We’re thrilled to launch these comprehensive tools,” said Dr. Eran Feldhay, Chief Executive Officer at OpenDNA. “PolyRisk+ and TotalRisk+ offer physicians and their patients actionable insights – long before symptoms appear – across a broad span of health domains.”
Why This Matters
Precision prevention in practice – Polygenic risk scoring is becoming a critical driver for proactive care. OpenDNA’s expanded tests enable clinicians to use genetic risk profiles to inform earlier screening and preventative strategies.
Physician-guided interpretation – Both tests are ordered through healthcare providers, ensuring results are contextualized, explained, and translated into preventive or monitoring strategies – addressing a common gap in direct-to-consumer testing.
Beyond cardiometabolic and cancer – By adding autoimmune, neurological, and respiratory disorders to the testing spectrum, OpenDNA supports more tailored monitoring and management for diverse patient populations.
Test Overview
PolyRisk+ – Polygenic, physician-ordered test covering 30 indications for stratifying risk across multiple diseases.
TotalRisk+ – Combines polygenic and monogenic data with clinical insights, offering a more comprehensive risk assessment for inherited and complex conditions.
Access and Availability
Both PolyRisk+ and TotalRisk+ are available to physicians now. Samples are collected via cheek swab, with results delivered through a secure provider portal that includes interpretive reporting and follow-up guidance.
